ライフサイエンスコーパス: Abbott

1 l were 19% (Monitor), 22% (TaqMan), and 25% (Abbott).

2 TnT (Roche), hs-cTnI (Siemens), and hs-cTnI (Abbott).

3 A new rapid test, Determine (Abbott, Abbott Park, Ill.), detects HIV type 1 (HIV-1) a

4 cquired immunodeficiency syndrome, Bragdon v Abbott, addressed this trend by ruling that a woman with

5 Roche Elecsys SARS-CoV-2 total antibody and Abbott Alinity SARS-CoV-2 IgG assays; a subset of 55 sam

6 agNA Pure LC instrument (Roche RUO-MPLC) and Abbott analyte-specific reagents (ASR) with QIAGEN sampl

7 libitum meals were highly variable, with the Abbott and Dexcom systems resulting in within-subject in

8 Abbott and Gen-Probe confirmed discrepant results by alt

9 obtained from plasma specimens tested by the Abbott and QIAGEN tests were in very close agreement (me

10 that the sensitivity and linear range of the Abbott and Roche RT-PCR assays enable them to be used fo

11 ott RealTime HIV-1 test on the m2000 system (Abbott), and the Roche TaqMan HIV-1 test, v2.0 (TaqMan).

12 of Basel, University Hospital Basel, Roche, Abbott, and Singulex.

13 genotyping methodologies supplied by Bayer, Abbott, and Third Wave Technologies.

14 e SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbott] and ID Now COVID-19 [abbreviated IDNOW; Abbott])

15 ott] and ID Now COVID-19 [abbreviated IDNOW; Abbott]) and a laboratory-developed test (modified CDC 2

16 hsTnI was measured using the Abbott ARCHITECT assay at baseline and 6 months in patie

17 Studies for the Abbott ARCHITECT HCV Ag assay had the highest quality, w

18 tested for SARS-CoV-2 IgG antibody using the Abbott Architect immunoassay targeting the nucleocapsid

19 ections was additionally evaluated using the Abbott Architect SARS-CoV-2 IgM assay.

20 of circulating high-sensitivity troponin I (Abbott ARCHITECT), with acute respiratory distress syndr

21 d specificity of the assays were as follows: Abbott ARCHITECT, 93.4% (95% CI, 90.1% to 96.4%) and 98.

22 on (HIV Ag/Ab Combo) assays (the Bio-Rad GS, Abbott Architect, and Bio-Rad BioPlex 2200 assays) was e

23 In 3 quantitative studies using Abbott ARCHITECT, HCVcAg correlated closely with HCV RNA

24 tion was obtained for the Roche RUO-MPLC and Abbott ASR-Q (R(2) = 0.84 and R(2) = 0.93, respectively)

25 stems showed acceptable reproducibility, the Abbott ASR-Q being the most reproducible of the three sy

26 r study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable results and agreed suff

27 eagents (ASR) with QIAGEN sample processing (Abbott ASR-Q) showed a sensitivity of 1.0 log(10) IU/ml

28 respectively), with better agreement for the Abbott ASR-Q.

29 en the two assays, which is given as log(10) Abbott assay measure = 0.032 + 1.01 log(10) Bayer assay

30 h correlation between the Xpert HIV-1 VL and Abbott assay results (r(2) = 0.92; P < 0.001).

31 re appeared to be an enhanced ability of the Abbott assay to detect dual infections, especially in th

32 values obtained by Xpert HIV-1 VL assay and Abbott assay was 0.34 log10 copies/ml (95% confidence in

33 hs-cTnI was measured (Abbott assay) using sex-specific 99th percentiles (women

34 boratory-based Abbott m2000sp/m2000rt assay (Abbott assay).

35 By the Abbott assay, 90% (53/59) had HCV RNA <LLOQ, of whom 1 p

36 sults by the participants were 96.6% for the Abbott assay, 96.3% for the Roche Cobas assay, 94.5% for

37 r assay, and only 77 of 137 specimens by the Abbott assay.

38 Both the POC Xpert HIV-1 VL and Abbott assays were performed on specimens sampled from 2

39 in had HCV RNA <LLOQ at EOT by the Roche and Abbott assays, but only 38 achieved SVR12 (PPV, 69%).

40 echnologies, the AMP CT (Gen-Probe) and LCx (Abbott) assays.

41 ic emptying (scintigraphy, 100 mL of Ensure (Abbott Australia, Kurnell, Australia) with 20 MBq Tc-sup

42 oglobulin M (IgM) test, was developed on the Abbott AxSYM analyzer.

43 ormance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV cult

44 ese results show that the sensitivity of the Abbott C. trachomatis LCR test is affected by the presen

45 We report the use of adalimumab (Abbott, Canada, Inc.) for orbital myositis in a patient

46 V (Fisher Scientific, Hanover Park, IL), and Abbott CMV (Abbott Park, IL).

47 ng the cTnT, hs-cTnI (Siemens), and hs-cTnI (Abbott) concentrations at 0 and 180 minutes, 1 (11%), 0,

48 In this issue of Neuron, Sussillo and Abbott describe a new learning rule that helps harness t

49 ing; those who accepted were tested with the Abbott Determine and Trinity Biotech Capillus SR tests i

50 Both antibodies are used in Abbott diagnostic assays on AxSYM, IMx, and Architect pl

51 standard, the PBP2a SA culture colony test (Abbott Diagnostics) exhibited 100% sensitivity and speci

52 Architect HIV Ag/Ab Combo [HIV Combo] assay; Abbott Diagnostics) in 2,744 HIV antibody-negative sampl

53 was measured with a high-sensitivity assay (Abbott Diagnostics, Abbott Park, IL).

54 cordance between the Ortho/ECi assay and the Abbott EIA were 97.78, 93.54, and 97.66% for anti-HCV an

55 ormance, six groups of sera prescreened with Abbott EIAs were assayed: anti-HCV-negative samples (n =

56 esting of the 200 prospective specimens, the Abbott, Elitech, EraGen, and Focus PCR assays demonstrat

57 convalescent patients, sensitivities of the Abbott, Epitope, Euroimmun, and Ortho-Clinical anti-SARS

58 The sensitivities of the Abbott, Epitope, Euroimmun, and Ortho-Clinical IgG assay

59 1.2%, and 99.6%/92.5%, respectively, for the Abbott, Epitope, Euroimmun, and Ortho-Clinical IgG assay

60 The Abbott, EraGen, Elitech, Focus, and LDT PCR assays perfo

61 cent-phase sera and high specificity for the Abbott, Euroimmun, and Ortho-Clinical anti-SARS-CoV-2 Ig

62 ified using average surface roughness Ra and Abbott-Firestone curves.

63 ous measurements from Dexcom G4 Platinum and Abbott Freestyle Libre Pro CGMs during 28 inpatient days

64 ily); 13 (57%), were serum HBV DNA positive (Abbott Genostics, Abbott Laboratories, Chicago, IL) at s

65 The Abbott HBV RUO Sequencing assay (Abbott Molecular Inc.,

66 The Abbott HBV RUO Sequencing assay provided a convenient an

67 e Trugene HBV Genotyping kit (n = 7) and the Abbott HBV RUO Sequencing assay showed minor differences

68 RNA (version 3.0) branched DNA assay and the Abbott HCV analyte-specific reagent real-time PCR assay,

69 have recently become commercially available (Abbott HCV Genotype ASR).

70 stratification threshold (<5 ng/L) using the Abbott high-sensitivity troponin I assay.

71 e high-sensitivity (hs) cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche) among 2300 consecutive patients

72 heid Xpert Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW], and GenMark ePlex SARS-

73 sent here the results of comparisons between Abbott ID Now COVID-19 and Cepheid Xpert Xpress SARS-CoV

74 iral transport media and comparisons between Abbott ID Now COVID-19 and Cepheid Xpert Xpress SARS-CoV

75 we sought to evaluate the recently released Abbott ID Now COVID-19 assay, which is capable of produc

76 ess of method of collection and sample type, Abbott ID Now COVID-19 had negative results in a third o

77 Abbott ID Now performance was similar to RT-LAMP of crud

78 enMark ePlex) and point-of-care instruments (Abbott ID NOW).

79 rt media for Cepheid and dry nasal swabs for Abbott ID Now.

80 Qualitative agreement between the Abbott IgG and Roche total antibody assays was 98.7% (65

81 etermined using pre-COVID-19 samples for the Abbott IgG and Roche total antibody assays were 99.65% (

82 Two nucleocapsid antibody tests (Abbott IgG and Roche total antibody) and one spike prote

83 es in a hemodialysis population, we used the Abbott IgG assay with the Architect system to test serum

84 with the Abbott IgM assay were 92.7% (51/55, Abbott IgG) and 85.5% (47/55, Roche total antibody).

85 (47.1%), and 22 (43.1%) were reactive by the Abbott IgG, Roche total antibody, and Abbott IgM assays,

86 Qualitative agreements with the Abbott IgM assay were 92.7% (51/55, Abbott IgG) and 85.5

87 by the Abbott IgG, Roche total antibody, and Abbott IgM assays, respectively, with sampling times 0 t

88 HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical

89 demonstrates that, consistent with Bragdon v Abbott, individuals with asymptomatic HIV have widesprea

90 and the LCx nucleic acid amplification test (Abbott Industries, Abbott Park, Ill.).

91 rdance of viral genotype quantitation of the Abbott investigational use only RealTime HCV (RealTime)

92 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated,

93 tion of anti-SARS-CoV-2 IgG antibodies, from Abbott Laboratories (Abbott Park, IL), Epitope Diagnosti

94 Drug discovery efforts at Abbott Laboratories have led to the identification of in

95 problems can occur during routine use of the Abbott Laboratories LCx assay for Chlamydia trachomatis

96 mples with discordant results were tested by Abbott Laboratories Micro-Particle Immunoassay (M-EIA) a

97 Recent efforts from the Abbott Laboratories resulted in the development of the a

98 Diagnostics) and ligase chain reaction LCR (Abbott laboratories) and compared three PCR specimen-pro

99 d compared with an enzyme immunoassay (EIA) (Abbott Laboratories) licensed by the Food and Drug Admin

100 The ID Now influenza A & B 2 (ID Now) assay (Abbott Laboratories), Cobas influenza A/B nucleic acid t

101 obe System Chlamydia trachomatis Assay (LCx; Abbott Laboratories), the APTIMA Combo 2 Assay (AC2; Gen

102 tion obtained by ligase chain reaction (LCR; Abbott Laboratories).

103 or the ETA/B, A-182086, receptor antagonist (Abbott Laboratories, Abbott Park, IL) directly to the pr

104 nty Wicklow, Ireland) and Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL) rapid tests in a r

105 anti-HCV with confirmation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse trans

106 enzimidazole-4-carboxamide, dihydrochloride; Abbott Laboratories, Abbott Park, IL), and the DNA-damag

107 d.) and influenza A virus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.) for the detectio

108 The Abbott LCx Neisseria gonorrhoeae assay (Abbott Laboratories, Abbott Park, Ill.) uses a ligase ch

109 Ligase chain reaction (LCR) (Abbott Laboratories, Abbott Park, Ill.) with first-catch

110 determined by the Auszyme Monoclonal assay (Abbott Laboratories, Abbott Park, Ill.), was 0.56% (39 o

111 ifferent enzyme-linked immunosorbent assays (Abbott Laboratories, Abbott Park, Ill.; Embrabio, Sao Pa

112 ed (ligase chain reaction [LCx Probe System; Abbott Laboratories, Abbott Park, Ill.]; PCR [Amplicor;

113 ter-based leaflet repair with the MitraClip (Abbott Laboratories, Abbott Park, Illinois) is accomplis

114 Absorb Bioresorbable Vascular Scaffold 1.1 (Abbott Laboratories, Abbott Park, Illinois).

115 titutes of Health, University of California, Abbott Laboratories, and the Centers for Disease Control

116 re serum HBV DNA positive (Abbott Genostics, Abbott Laboratories, Chicago, IL) at study entry.

117 on in the LCx Chlamydia assay (LCx-CT assay; Abbott Laboratories, Chicago, Ill.) by using a commercia

118 d with the extended-release niacin (Niaspan, Abbott Laboratories, Chicago, Illinois, USA).

119 Abbott Laboratories, Genentech, and National Cancer Inst

120 tional Cancer Institute, Sanofi-Aventis, and Abbott Laboratories.

121 PRIMARY FUNDING SOURCE: Abbott Laboratories.

122 , Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories.

123 ction in urine samples with three NAATs: the Abbott LCx (LCx), BD ProbeTec ET (ProbeTec), and Gen-Pro

124 The Abbott LCx assay is a rapid, sensitive method for detect

125 cially available HIV RNA quantitative tests: Abbott LCx HIV RNA Quantitative assay (LCx), Bayer Versa

126 The Abbott LCx ligase chain reaction (LCR) assay for the sim

127 The Abbott LCx Neisseria gonorrhoeae assay (Abbott Laborator

128 catch urine [FCU]) initially positive by the Abbott LCx Probe System Chlamydia trachomatis Assay (LCx

129 icile toxin genes, the IMDx C. difficile for Abbott m2000 Assay (IMDx) and the BD Max Cdiff Assay (Ma

130 We utilised residual material from Abbott m2000 Ct diagnostic tests to sequence 99 ocular C

131 only RealTime HCV (RealTime) assay using the Abbott m2000 platform and compared the results to those

132 ergency Use Authorization (EUA) assay on the Abbott m2000 platform.

133 This assay is designed to be performed on an Abbott m2000 real-time instrument system, which consists

134 he GeneXpert CT/NG assay (GeneXpert) and the Abbott m2000 RealTime CT (m2000) assay were compared to

135 pliPrep/COBAS TaqMan HIV-1 v.2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all sub

136 les subsequently retested negative using the Abbott m2000 RealTime HIV-1 assay, which targets the int

137 hroughput laboratory analyzers (Roche Cobas, Abbott m2000, and Hologic Panther Fusion) and 167 to 511

138 PVLs were measured using Abbott m2000rt real-time polymerase chain reaction, and

139 HIV-1 VL assay against the laboratory-based Abbott m2000sp/m2000rt assay (Abbott assay).

140 sma samples from 40 patients enrolled in the Abbott M97-720 trial at baseline (pretherapy) and weeks

141 Abbott, MD, and Donald Tan, MD, comprised recognized exp

142 second laser-enabled (150-kHz IntraLase iFS; Abbott Medical Optics Inc) wavefront-guided ablation.

143 OL (one-piece Tecnis-1 or three-piece AR40E, Abbott Medical Optics Inc.) had been previously placed.

144 es, Inc, Fort Worth, Texas, USA), or ZA9003 (Abbott Medical Optics Johnson & Johnson Vision, Inc) IOL

145 urgery and in-the-bag implantation of ZCB00 (Abbott Medical Optics Johnson & Johnson Vision, Inc, Abb

146 us ultrasound on transverse ultrasound using Abbott Medical Optics' (AMO) WhiteStar Signature Pro wit

147 (Alcon Laboratories), or Tecnis Multifocal (Abbott Medical Optics) lenses.

148 The AMO WhiteStar Signature Pro machine (Abbott Medical Optics) with the Ellips FX handpiece and

149 x CustomVue Star S4 IR excimer laser system; Abbott Medical Optics), and the fellow eye received WFO

150 ide cut made with the 150 kHz IntraLase iFS (Abbott Medical Optics).

151 derwent implantation of the Baerveldt (BGI) (Abbott Medical Optics, Abbott Park, IL) or the Molteno3

152 (GDD) surgery (Baerveldt 350, Baerveldt 250 [Abbott Medical Optics, Abbott Park, IL], or Ahmed FP7 [N

153 A Signature (Abbott Medical Optics, Inc) phacoemulsification machine

154 o Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc, Santa Ana, CA) using a stand

155 o Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc., Santa Ana, CA) using a stan

156 created using the Catalys femtosecond laser (Abbott Medical Optics, Inc., Santa Ana, CA).

157 Tecnis ZM900 diffractive multifocal lenses (Abbott Medical Optics, Santa Ana, CA) or Akreos AO monof

158 side cut made with the 60 kHz IntraLase FS (Abbott Medical Optics, Santa Ana, CA) or an inverted 130

159 ere created using the 150-kHz IntraLase iFS (Abbott Medical Optics, Santa Ana, CA).

160 Texas, USA), or Tecnis +4D Multifocal (MF) (Abbott Medical Optics, Santa Ana, California, USA) IOL.

161 d to percutaneous repair with the MitraClip (Abbott, Menlo Park, California) device or conventional m

162 l valve with a particular device (MitraClip, Abbott, Menlo Park, California) has emerged as a novel t

163 ive nonculture tests included Chlamydiazyme (Abbott), MicroTrak direct fluorescent antibody (DFA) (Sy

164 One version is distributed by Abbott Molecular and the other by QIAGEN.

165 matis and Neisseria gonorrhoeae developed by Abbott Molecular Inc.

166 The PLEX-ID Flu assay (Abbott Molecular Inc., Des Plaines, IL) incorporates mul

167 The Abbott HBV RUO Sequencing assay (Abbott Molecular Inc., Des Plaines, IL), which combines

168 ultures; the Ibis T5000 universal biosensor (Abbott Molecular); and 16S 454 FLX titanium series pyros

169 FISH was performed using UroVysion (Abbott Molecular, Inc, Des Plaines, IL) and classified a

170 screening assays, the Abbott RealTime CT/NG (Abbott Molecular, Inc., Des Plaines, IL), the Cobas CT/N

171 The introduction of the Abbott mPLUS feature, with the capacity for extended use

172 me-linked immunosorbent assay (ELISA) tests (Abbott Murex HIV Ag/Ab combination and Vironostika Unifo

173 he ambulatory Minneapolis Heart Institute at Abbott Northwestern Hospital.

174 natomical voltage mapping (EnSite Precision, Abbott) of left atrium and PVs were performed using a co

175 6, receptor antagonist (Abbott Laboratories, Abbott Park, IL) directly to the preservation solution (

176 the Baerveldt (BGI) (Abbott Medical Optics, Abbott Park, IL) or the Molteno3 glaucoma implant (MGI)

177 and Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL) rapid tests in a reference laboratory u

178 mation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse transcriptase-polymerase c

179 amide, dihydrochloride; Abbott Laboratories, Abbott Park, IL), and the DNA-damaging topoisomerase I i

180 -2 IgG antibodies, from Abbott Laboratories (Abbott Park, IL), Epitope Diagnostics, Inc.

181 high-sensitivity assay (Abbott Diagnostics, Abbott Park, IL).

182 ientific, Hanover Park, IL), and Abbott CMV (Abbott Park, IL).

183 t 350, Baerveldt 250 [Abbott Medical Optics, Abbott Park, IL], or Ahmed FP7 [New World Medical Inc, R

184 irus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.) for the detection of respiratory viru

185 eria gonorrhoeae assay (Abbott Laboratories, Abbott Park, Ill.) uses a ligase chain reaction (LCR) am

186 e chain reaction (LCR) (Abbott Laboratories, Abbott Park, Ill.) with first-catch urine specimens was

187 A new rapid test, Determine (Abbott, Abbott Park, Ill.), detects HIV type 1 (HIV-1) and HIV-2

188 szyme Monoclonal assay (Abbott Laboratories, Abbott Park, Ill.), was 0.56% (39 of 6,986 repeatedly re

189 acid amplification test (Abbott Industries, Abbott Park, Ill.).

190 d immunosorbent assays (Abbott Laboratories, Abbott Park, Ill.; Embrabio, Sao Paulo, Brazil; Organon

191 tion [LCx Probe System; Abbott Laboratories, Abbott Park, Ill.]; PCR [Amplicor; Roche Molecular Syste

192 using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the results with surg

193 olimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE (A Randomized Com

194 air with the MitraClip (Abbott Laboratories, Abbott Park, Illinois) is accomplished with an implantab

195 Vascular Scaffold 1.1 (Abbott Laboratories, Abbott Park, Illinois).

196 edical Optics Johnson & Johnson Vision, Inc, Abbott Park, Illinois, USA), SN60WF (Alcon Laboratories,

197 We established HCV genotype using an Abbott platform, and HCV subtype with PCR amplification.

198 says and 0.96 (95% CI, 0.90 to 0.98) for the Abbott Qualitative assay.

199 (95% CI, 0.97 to 1.00) for the AmpliSens and Abbott Qualitative assays and 0.99 (95% CI, 0.96 to 1.00

200 NA not detected (RNA(-)), as measured by the Abbott Real Time assay.

201 echnical and clinical feasibility of the new Abbott real-time PCR C. trachomatis/N. gonorrhoeae assay

202 We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C

203 ng the High Pure System and reanalyzed using Abbott RealTime (limits of detection, 15.1 IU/ml versus

204 The Abbott RealTime (RT) HCV assay targets the 5' untranslat

205 of the patients with undetectable HCV RNA by Abbott RealTime achieved a sustained virologic response.

206 le HCV RNA as the cutoff, the more sensitive Abbott RealTime assay would identify fewer patients elig

207 eviously established in other studies of the Abbott RealTime assay, to determine eligibility for shor

208 oofer (NorChip), Aptima HPV (Gen-Probe), and Abbott RealTime assays, the BD HPV test, and CINtec p16(

209 ens and three separate screening assays, the Abbott RealTime CT/NG (Abbott Molecular, Inc., Des Plain

210 nce characteristics of the newly FDA-cleared Abbott RealTime CT/NG assay (where "CT" stands for Chlam

211 In summary, we conclude that the Abbott RealTime CT/NG assay is an accurate and automated

212 The Abbott RealTime CT/NG assay offers C. trachomatis and N.

213 e overall sensitivity and specificity of the Abbott RealTime CT/NG assay were 92.4% and 99.2% for C.

214 luate the performance characteristics of the Abbott RealTime CT/NG assay, a multiplex real-time PCR a

215 Specimens were tested with the automated Abbott RealTime CT/NG assay, Aptima Combo 2 assay (Gen-P

216 Abbott RealTime had 93.3% sensitivity, 27.3% specificity

217 The Abbott RealTime HBV assay targets the N-terminal region

218 fined as HBV DNA levels >15 IU/mL, using the Abbott RealTime HBV DNA assay.

219 irus (HBV) quantification were assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas

220 s, Cobas AmpliPrep/CobasTaqMan (CAP/CTM) and Abbott RealTime HCV (ART) assays.

221 sing the Roche COBAS TaqMan HCV test and the Abbott RealTime HCV assay.

222 sults were compared to quantification by the Abbott RealTime HCV assay.

223 hich was also similarly misquantified by the Abbott RealTime HCV assay.

224 rt HCV Viral Load assay in comparison to the Abbott RealTime HCV assay.

225 The Abbott RealTime HCV Genotype II RUO (research use only)

226 the Roche High Pure System/Cobas TaqMan and Abbott RealTime HCV RNA assays and the impacts of differ

227 red to those tested retrospectively with the Abbott RealTime HCV RNA test (ART).

228 uncture and finger-stick collection with the Abbott RealTime HCV Viral Load assay (gold standard).

229 1 v1.5 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA 3

230 pliPrep/Cobas TaqMan HIV-1 test (RT) and the Abbott RealTime HIV-1 assay (AR), that utilize real-time

231 curacy of HIV-1 viral load results using the Abbott RealTime HIV-1 assay and (ii) evaluate the effect

232 discordant results were observed between the Abbott RealTime HIV-1 assay and the COBAS AmpliPrep/COBA

233 HIV-1 Quant Dx assay in comparison with the Abbott RealTime HIV-1 assay using plasma and cervicovagi

234 ect on viral load results as measured by the Abbott RealTime HIV-1 assay.

235 accurate quantification of HIV-1 RNA in the Abbott RealTime HIV-1 assay.

236 this design strategy was demonstrated in the Abbott RealTime HIV-1 assay.

237 70% of results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than 0.5log10.

238 negative specimens were also tested with the Abbott RealTime HIV-1 Qual assay (RealTime).

239 AS TaqMan (CAP/CTM) HIV-1 Qual test, and the Abbott RealTime HIV-1 Qualitative assay.

240 Roche Amplicor Monitor, v1.5 (Monitor), the Abbott RealTime HIV-1 test on the m2000 system (Abbott),

241 plicor Monitor v1.5 showed a tendency of the Abbott RealTime HIV-1 to under-estimate results while th

242 The Abbott RealTime HIV-1 viral load assay uses primers and

243 erage intra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0-5.1%) and 5.

244 Bias data comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monit

245 The Abbott RealTime human immunodeficiency virus type 1 (HIV

246 nly) assay was evaluated using the automated Abbott RealTime m2000 system.

247 The Abbott RealTime MTB assay is a nucleic acid amplificatio

248 (coefficient of variation = 2.95%) using the Abbott RealTime SARS-CoV-2 Emergency Use Authorization (

249 he Cobas AmpliPrep/Cobas TaqMan test and the Abbott RealTime test, are FDA cleared for use with EDTA

250 eligible for shorter treatment duration with Abbott RealTime versus 72% with the High Pure System.

251 However, using <12 IU/ml for Abbott RealTime, a similar proportion (74%) would be eli

252 [95% CI 23-38]) of 150 participants based on Abbott RealTime.

253 RNA by the High Pure System or <12 IU/ml by Abbott RealTime; however, 92% of the patients with undet

254 of incremental glycemic responses ranked by Abbott resulted in 50 +/- 10% (P = 0.0002) less glycemic

255 the Abbott TaqMan analyte-specific reagent (Abbott reverse transcription-PCR [RT-PCR]), Roche TaqMan

256 ening assay (96.2%, 86.0%, and 73.9% for the Abbott, Roche, and BD tests, respectively) in sample typ

257 lidated) was 89.1%, 82.1%, and 59.2% for the Abbott, Roche, and BD tests, respectively.

258 Abbott RT-PCR and Roche RT-PCR detected all 28 replicate

259 (1 through 4) were tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

260 For Abbott RT-PCR, mean viral load values were 0.61 to 0.96

261 another weak-affinity fragment derived from Abbott's ABT-737 led to an improvement of the binding af

262 Rapid Test, and point-of-care tests such as Abbott's ID NOW COVID-19 Test.

263 M), real-time PCR with molecular beacon, and Abbott's ligase chain reaction (LCx).

264 hroughput serological assays (HTSAs) and the Abbott SARS-CoV-2 IgG assay quantify levels of antibodie

265 rate excellent analytical performance of the Abbott SARS-CoV-2 IgG test as well as the limited circul

266 Here, we evaluated the Abbott SARS-CoV-2 IgG test for detection of anti-SARS-Co

267 nti-HBsAg), in human serum was compared to a Abbott second-generation enzyme immunoassay (EIA 2.0).

268 r Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, MN, USA) compared with

269 re tested in multiple laboratories using the Abbott TaqMan analyte-specific reagent (Abbott reverse t

270 Comparison of plasma viral loads using the Abbott test and the Roche Amplicor Monitor test showed a

271 For plasma specimens, the Abbott test had a limit of detection of 2.3 log10 copies

272 ., Cockeysville, Md.) and influenza A virus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.

273 In addition, the Abbott test viral loads correlated with the Digene Hybri

274 e and after implementation of hs-cTnI assay (Abbott) using sex-specific 99th percentiles.

275 e-to-edge repair using the Mitraclip system (Abbott Vascular Devices, California, USA).

276 th Xience V everolimus-eluting stents (EES) (Abbott Vascular Devices, Santa Clara, California) at 1-y

277 ute of Neurological Disorders and Stroke and Abbott Vascular Solutions (formerly Guidant).

278 ute of Neurological Disorders and Stroke and Abbott Vascular Solutions.

279 occlusion patients treated with BRS (Absorb; Abbott Vascular) and second-generation drug-eluting sten

280 Absorb Bioresorbable Vascular Scaffold (BVS; Abbott Vascular) was the first FDA-approved device and w

281 d artery stenting or carotid endarterectomy (Abbott Vascular).

282 d percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the

283 and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE

284 ed post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).

285 Boston Scientific, Abbott Vascular, Medtronic, Cordis, Biosensors, The Medi

286 y and effectiveness of the MitraClip device (Abbott Vascular, Menlo Park, CA) is being evaluated in t

287 valve (MV) repair with the MitraClip device (Abbott Vascular, Menlo Park, California).

288 ith Absorb bioresorbable vascular scaffolds (Abbott Vascular, Santa Clara, CA).

289 imus-eluting bioresorbable scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) or treatment with

290 imus-eluting bioresorbable scaffold (Absorb; Abbott Vascular, Santa Clara, CA, USA) or treatment with

291 n everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, CA, USA).

292 n everolimus-eluting metallic stent (Xience; Abbott Vascular, Santa Clara, CA, USA).

293 allic drug-eluting stent (DES) implantation (Abbott Vascular, Santa Clara, California) and determine

294 red the safety and efficacy of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-elu

295 nd Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following stri

296 patients who received the MitraClip device (Abbott Vascular, Santa Clara, California) for mitral reg

297 y and effectiveness of the MitraClip device (Abbott Vascular, Santa Clara, California) in patients wi

298 In MitraClip (Abbott Vascular, Santa Clara, California), a usually con

299 nomannan in urine (Determine TB-LAM Ag test, Abbott, Waltham, MA, USA [formerly Alere]; TB-LAM) and c

300 ong agreement (Cohen's kappa, 0.76 to 0.82), Abbott was more likely to detect HIV-1 RNA levels of >50

301 A deflectable sheath (Agilis, Abbott) was used to maneuver the ablation catheter.